Long-term macrolides in diffuse interstitial lung diseases

Paola Faverio, Francesco Bini, Adriano Vaghi, Alberto Pesci

Source: Eur Respir Rev, 26 (146) 170082; 10.1183/16000617.0082-2017

Journal Issue: October

Disease area: Interstitial lung diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Paola Faverio, Francesco Bini, Adriano Vaghi, Alberto Pesci. Long-term macrolides in diffuse interstitial lung diseases. Eur Respir Rev, 26 (146) 170082; 10.1183/16000617.0082-2017

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Antibiotics in interstitial lung diseases Source: Eur Respir Monogr 2017; 75: 264-275 Year: 2017
Experience with antifibrotics treatment in progressive interstitial lung diseases non-IPF Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases Year: 2021
Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019
Clubbing in patients with fibrotic interstitial lung diseases Source: International Congress 2017 – ILDs: clinical problems Year: 2017
Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019
Diffuse parenchymal lung diseases Source: ERS Course 2018 - Summer school of adult respiratory medicine Year: 2018
Diffuse parenchymal lung diseases Source: ERS Course 2019 - Summer school of adult respiratory medicine Year: 2019
Diffuse parenchymal lung diseases Source: ERS Skills Course 2017 - Summer school of adult respiratory medicine Year: 2017
Diffuse parenchymal lung diseases Source: ERS Skills Course 2016 Year: 2016
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019 Year: 2019
Alveoscopy in diffuse interstitial lung disease Source: Eur Respir J 2007; 30: Suppl. 51, 244s Year: 2007
Interstitial lung diseases and systemic disorders with lung involvement Source: ERS Skills Course 2017 - Summer school of paediatric respiratory medicine Year: 2017
Interstitial lung diseases and systemic disorders with lung involvement Source: ERS Skills Course 2016 Year: 2016
Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015
Rare interstitial lung diseases Source: School Course 2014 - Interstitial lung diseases Year: 2014
Comparison of registries of interstitial lung diseases in three European countries Source: Eur Respir J 2001; 18: 114S-118S Year: 2001
Cytomegalovirus antigenemina in idiopathic interstitial pneumonias and collagen vascular disease-related lung diseases treated with immunosuppressive drugs Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008
Nitrofurantoin-induced interstitial lung disease Source: Annual Congress 2012 - Viral infections and rare respiratory infections Year: 2012